Mr. Zachary Goldenberg reports

VIMY PHARMACEUTICALS ANNOUNCES BROKERED PRIVATE PLACEMENT OF SUBSCRIPTION RECEIPTS

Further to Vimy Pharmaceuticals Inc. and Harmony Acquisitions Corp.'s press release dated Aug. 6, 2026, announcing the entering into of a non-binding letter of intent to complete a business combination transaction which will constitute a reverse takeover of Harmony, Vimy Pharma has launched a best efforts brokered private placement of subscription receipts of the company, at a price of $3.00 per subscription receipt, for gross proceeds of up to $10,000,200. The offering price implies an enterprise value of the company of approximately $80-million, prior to completion of the offering and after giving effect to the share split (as defined below).

Vimy Pharma has engaged Beacon Securities Ltd. to act as lead agent and sole bookrunner, on behalf of a syndicate of agents including Haywood Securities Inc. and Research Capital Corp., in connection with the offering. Vimy Pharma has granted the agents an option, exercisable in whole or in part at any time up to 48 hours prior to closing date of the offering, to offer up to an additional 15 per cent of the subscription receipts at the offering price.

The subscription receipts will be issued pursuant to a subscription receipt agreement to be entered into among Vimy Pharma, Harmony, the lead agent and a Canadian trust company acting as subscription receipt agent. On the closing date, the net proceeds of the offering will be placed in escrow with the subscription receipt agent and, together with any interest earned thereon, will be held as escrowed funds. Upon satisfaction of the escrow release conditions set out in the subscription receipt agreement, each subscription receipt will be exchanged, without payment of any additional consideration and without further action on the part of the holder, for one common share of the company, and the escrowed funds, net of the escrowed portion of the agents' fees and expenses, will be released to Vimy Pharma. If the escrow release conditions are not satisfied or waived by 5 p.m. ET on the date which is 120 days following the closing date (subject to extension by up to 30 days by agreement between Vimy Pharma and the lead agent), or if prior to such time Vimy Pharma advises the agents or announces publicly that it does not intend to satisfy the escrow release conditions, the subscription receipts will be cancelled and the subscription receipt agent will return to holders of subscription receipts, within two business days, an amount equal to the aggregate offering price of the subscription receipts held by them together with their pro rata portion of any interest earned thereon, less applicable withholding taxes, if any.

Vimy Pharma will pay the agents a cash commission equal to 6.0 per cent of the gross proceeds of the offering, reduced to 3.0 per cent in respect of certain investors on a mutually agreed president's list and issue to the agents compensation options equal to 6.0 per cent of the number of subscription receipts sold in connection with the offering (including the agents' option), also reduced to 3.0 per cent in respect of such president's list investors. Each compensation option will be exercisable into one common share at the offering price for a period of 24 months from the date of the release of the escrowed funds. Fifty per cent of the cash commission will be payable on the closing date, and the remaining 50 per cent will be payable on the release date. The compensation options will be issued to the agents on the closing date.

The company intends to use the net proceeds of the offering to advance research and development of new products in the company's portfolio of generic pharmaceutical products, including its generic semaglutide injection program, to accelerate entry into international markets, to support direct-to-consumer advertising, to build the VimyDirect on-line pharmacy platform, to support Canadian manufacturing of preapproval inventory, regulatory and commercialization activities, and for transaction expenses, working capital and general corporate purposes of the resulting issuer (as defined herein).

The resulting issuer shares (as defined herein), including the resulting issuer shares issuable upon exercise of the resulting issuer compensation options (as defined below), are expected to be listed on the TSX Venture Exchange, with conditional listing approval to be obtained prior to completion of the transaction. The trading symbol VIMY has been reserved for the resulting issuer shares.

The offering is expected to close on or about the week of Sept. 14, 2026, and is subject to the company receiving all necessary regulatory approvals, including the approval of the TSX-V.

Vimy Pharma is not a reporting issuer in any province or territory of Canada, its securities are not listed on any stock exchange in Canada and there is currently no public market for its securities. The subscription receipts, and any securities issuable upon the exchange thereof, will not be transferable under the laws of Canada, except pursuant to applicable statutory exemptions and subject to any control person distribution restrictions, until the date that is four months and a day after the date Vimy Pharma becomes a reporting issuer in any province or territory of Canada, in accordance with National Instrument 45-102 -- Resale of Securities. Upon completion of the transaction and satisfaction of the escrow release conditions, the resulting issuer shares and the securities issuable upon exercise of the resulting issuer compensation options will not be subject to any hold period under applicable Canadian securities laws.

Transaction

Prior to the completion of the transaction, the company shall complete a share split of its issued and outstanding common shares on the basis of 34 postsplit common shares for every one presplit common share.

The transaction will constitute an arm's-length qualifying transaction for Harmony within the meaning of Policy 2.4 of the Corporate Finance Manual of the TSX-V. Upon closing of the transaction, the resulting issuer is expected to change its name to Vimy Pharmaceuticals and list as a Tier 2 issuer on the TSX-V, subject to TSX-V approval.

In connection with the transaction and the offering, each common share will be exchanged for one common share of the resulting issuer. In addition, each compensation option will be exchanged for one compensation option of the resulting issuer on a one-for-one basis, such that each resulting issuer compensation option will be exercisable to acquire one resulting issuer share on the same terms and conditions (including exercise price and expiry) as applied to the corresponding compensation option immediately prior to the effective time, subject only to customary adjustments. For further information on the transaction please see Harmony's press release dated Aug. 6, 2026, available on Harmony's SEDAR+ profile.

Overview of Vimy Pharma

Vimy Pharma is a Canadian pharmaceutical company focused on improving access to affordable medicines while supporting domestic pharmaceutical manufacturing capacity and long-term Canadian supply resilience. Vimy Pharma is advancing a portfolio of essential medicines as generic pharmaceutical products intended to support patients, health care systems and Canada's life sciences sector.

A strategic priority for the company is expanding access to innovative therapies through the development of generic alternatives to popular medicines. By combining domestic production with cost-efficient manufacturing and regulatory expertise, Vimy Pharma seeks to provide affordable treatment options while contributing to Canada's pharmaceutical sovereignty.

Earlier this year, Vimy Pharma completed one of its development programs and filed an abbreviated new drug submission (ANDS) with Health Canada, which has been found acceptable for review, for a generic version of Ozempic (semaglutide injection), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of Type 2 diabetes. Vimy Pharma has also filed an ANDS with Health Canada for a generic version of Wegovy (semaglutide injection), a GLP-1 receptor agonist indicated for weight management. Ozempic has been the highest-earning prescription medicine in Canada for the past four years with combined sales of semaglutide injection medicines in Canada totalling $3.5-billion in 2025, growing at 31 per cent over the previous year. Vimy Pharma undertook its development work in Canada and will carry out its commercial production domestically, with Canadian partners. Additionally, Vimy Pharma has established partnerships to support the many large and growing international markets for injectable semaglutide.

Vimy Pharma is led by an experienced management team, including former executives from Novo Nordisk, with broader organizational expertise spanning pharmaceutical development, manufacturing, regulatory affairs, commercialization and capital markets. Vimy Pharma is committed to long-term value creation through disciplined execution, innovation and the development of a sustainable domestic pharmaceutical ecosystem that serves patients, health care providers and government partners, and supports Canadian pharmaceutical supply resilience and access to medicines.

About Harmony Acquisitions Corp.

Harmony was incorporated under the Business Corporations Act (British Columbia) on May 7, 2021, and is a capital pool company listed on the TSX-V.

Advisers

Wildeboer Dellelce LLP is acting as legal counsel to Vimy Pharma in connection with the transaction and the offering, and Dentons Canada LLP is acting as legal counsel to the agents in connection with the offering.

We seek Safe Harbor.